A matrix metalloproteinase (MMP) inhibitor decreases growth of colon cancer peritoneal carcinomatosis and prolongs survival in BD IX rats.

被引：0
|
作者：
Aparicio, T [1 ]
Kermorgant, S [1 ]
Dessirier, V [1 ]
Lewin, MJM [1 ]
Lehy, T [1 ]
机构：
[1] Hop Bichat Claude Bernard, INSERM U10, F-75877 Paris 18, France
来源：
GASTROENTEROLOGY | 1998年 / 114卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
G2282
引用
收藏
页码：A558 / A558
页数：1
相关论文
共 17 条
  • [1] Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats
    Aparicio, T
    Kermorgant, S
    Dessirier, V
    Lewin, MJM
    Lehy, T
    CARCINOGENESIS, 1999, 20 (08) : 1445 - 1451
  • [2] A SYNTHETIC MATRIX METALLOPROTEINASE INHIBITOR DECREASES TUMOR BURDEN AND PROLONGS SURVIVAL OF MICE BEARING HUMAN OVARIAN-CARCINOMA XENOGRAFTS
    DAVIES, B
    BROWN, PD
    EAST, N
    CRIMMIN, MJ
    BALKWILL, FR
    CANCER RESEARCH, 1993, 53 (09) : 2087 - 2091
  • [3] Phosphoramidon, a novel matrix metalloproteinase inhibitor, inhibits significantly tumor growth independently of the application route in a rat model of peritoneal carcinomatosis
    Hribaschek, A
    Meyer, F
    Ridwelski, K
    Pross, M
    Habermann, P
    Halangk, W
    Lippert, H
    GASTROENTEROLOGY, 2004, 126 (04) : A776 - A776
  • [4] The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model
    Michael Lein
    Klaus Jung
    Bernhard Ortel
    Carsten Stephan
    Winfried Rothaug
    Rolf Juchem
    Manfred Johannsen
    Serdar Deger
    Dietmar Schnorr
    Stefan Loening
    Hans-Willi Krell
    Oncogene, 2002, 21 : 2089 - 2096
  • [5] The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model
    Lein, M
    Jung, K
    Ortel, B
    Stephan, C
    Rothaug, W
    Juchem, R
    Johannsen, M
    Deger, S
    Schnorr, D
    Loening, S
    Krell, HW
    ONCOGENE, 2002, 21 (13) : 2089 - 2096
  • [6] Effects of matrix metalloproteinase inhibitor ONO-4817 on morphological changes in chlorhexidine. Gluconate-induced peritoneal sclerosis rats.
    Ro, Y
    Hamada, C
    Io, H
    Inaba, M
    Hayashi, K
    Sho, I
    Fukui, M
    Horikoshi, S
    Tomino, Y
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 593A - 593A
  • [7] A SYNTHETIC MATRIX METALLOPROTEINASE INHIBITOR DECREASES TUMOR BURDEN AND PROLONGS SURVIVAL OF MICE BEARING HUMAN OVARIAN-CARCINOMA XENOGRAFTS (VOL 53, PG 2087, 1993)
    DAVIES, B
    CANCER RESEARCH, 1993, 53 (15) : 3652 - 3652
  • [8] No associations of a set of SNPs in the Vascular Endothelial Growth Factor (VEGF) and Matrix Metalloproteinase (MMP) genes with survival of colorectal cancer patients
    Dan, Lydia A.
    Werdyani, Salem
    Xu, Jingxiong
    Shestopaloff, Konstantin
    Hyde, Angela
    Dicks, Elizabeth
    Younghusband, Ban
    Green, Jane
    Parfrey, Patrick
    Xu, Wei
    Savas, Sevtap
    CANCER MEDICINE, 2016, 5 (09): : 2221 - 2231
  • [9] Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer
    Ohta, M
    Konno, H
    Tanaka, T
    Baba, M
    Kamiya, K
    Oba, K
    Kaneko, T
    Syouji, T
    Igarashi, A
    Nakamura, S
    JAPANESE JOURNAL OF CANCER RESEARCH, 2001, 92 (06): : 688 - 695
  • [10] Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: Inhibition of matrix metalloproteinases in pancreatic cancer
    Kilian, M.
    Gregor, J. I.
    Heukamp, I.
    Hanel, M.
    Ahlgrimm, M.
    Schimke, I.
    Kristiansen, G.
    Ornmer, A.
    Walz, M. K.
    Jacobi, C. A.
    Wenger, F. A.
    PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2006, 75 (06): : 429 - 434
12